Ragaglitazar

DB06533ExperimentalSmall molecule

Investigated for use/treatment in diabetes mellitus type 2.

Chemical structure of Ragaglitazar
Primary indication
Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight
C25H25NO5 · 419.477 g/mol (avg)
Code names
NN 622

Resolves to

Compound
UNIIQ5ELR5A7Y5CAS222834-30-2ChEMBLCHEMBL24683
Structure
InChIKeyWMUIIGVAWPWQAW-XMMPIXPASA-NSMILESCCO[C@H](CC1=CC=C(OCCN2C3=CC=CC=C3OC3=C2C=CC=C3)C=C1)C(O)=O
Targets
Q07869PPARAP37231PPARG

What you can answer from here — as of March 06, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ragaglitazar, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In